Orexin Receptors

Efizonerimod alfa is a potent monoclonal antibody that functions as an OX40 activator. This reagent enhances T-cell activation and proliferation, making it particularly relevant for cancer research and immunotherapy studies. Its ability to modulate immune responses positions it as a valuable tool for investigating therapeutic strategies in oncology.

Orexin receptor antagonist 3 functions as an antagonist of the orexin receptors, specifically targeting OX receptors. This compound can modulate the activity of orexin, playing a significant role in the regulation of sleep-wake cycles and appetite. It is employed in research applications focused on sleep disorders, metabolic syndromes, and other conditions influenced by orexin signaling.

DORA-22 is a dual orexinergic receptor antagonist that targets orexin receptors OX1 and OX2, playing a critical role in regulating arousal, sleep, and appetite. It effectively alleviates sleep disruption and addresses memory impairment associated with sleep disorders. DORA-22 is useful for research applications related to insomnia and other sleep-related conditions.

GYKI-13380 is an appetite suppressant that acts primarily on neurochemical pathways involved in energy balance and hunger regulation. This compound demonstrates potential for study in neurological disorders related to appetite and metabolism. Researchers can utilize GYKI-13380 to explore its effects on weight management and the underlying mechanisms of appetite control.

OX-201 is a potent OX2R agonist that effectively crosses the blood-brain barrier, exhibiting an EC50 of 8.0 nM. This compound stimulates OX2R, leading to increased wakefulness and neuronal activation. Additionally, OX-201 facilitates the release of activity-dependent tau protein from neurons into the interstitial fluid of hippocampal tissues. It is a valuable tool for research into Alzheimer's disease and tauopathies.

OX2-2303 is a potent and selective antagonist of the orexin-2 receptor (OX2R), demonstrating exceptional binding affinity with a Ki value of 0.1 nM and over 890-fold selectivity for OX2R compared to OX1R. This compound is valuable for applications in central nervous system (CNS) research, particularly as a positron emission tomography (PET) radioligand, enabling the study of OX2R's role in various neurological processes.

Cleminorexton is an orally active agonist of the orexin-2 receptor (OX2R), exhibiting a pEC50 value between 9 and 10.4. This compound is primarily utilized in research related to narcolepsy and other disorders characterized by orexin deficiency and excessive daytime sleepiness. Its modulation of OX2R activity makes it a valuable tool for studying sleep-wake regulation and potential therapeutic interventions.

Orexin receptor modulator-1 is a selective modulator of orexin receptors, playing a vital role in the regulation of arousal, wakefulness, and appetite. It demonstrates significant biological activity in the context of substance addiction, anxiety, depression, and various stress-related disorders. This compound serves as a valuable tool for investigating the pathophysiology of disorders such as post-traumatic stress disorder, panic disorder, and seasonal affective disorder, as well as the modulation of pain and hypertension.

Ledasorexton is a potent oral agonist of the OX2 receptor (OX2R), exhibiting an EC50 of 0.99 nM. This compound has been demonstrated to induce wakefulness and promote alertness, making it a valuable tool for research into sleep regulation and associated disorders. Its specificity for the OX2R highlights its potential applications in studying neurobiology and pharmacology related to sleep and wakefulness.

Orexin receptor activator-1 is an agonist for the orexin receptor. This compound exhibits biological activity by modulating orexin signaling pathways, making it valuable for studying orexin-related disorders such as narcolepsy and obesity. Its application extends to research on sleep regulation and energy homeostasis, contributing to the understanding of various neurophysiological processes.

OX2R-IN-3 is a potent agonist of the type 2 orexin receptor (OX2R) with an EC50 value of less than 100 nM. This compound demonstrates significant biological activity in modulating orexin signaling pathways, making it a valuable tool for research in sleep disorders, energy homeostasis, and neurodegenerative diseases. OX2R-IN-3 can facilitate the exploration of OX2R-related functions in various physiological and pathological contexts.

YNT-3708 is an orexin receptor (OXR) agonist that demonstrates selective activation of OX1R and OX2R. It has EC50 values of 14.6 nM for OX1R and 277 nM for OX2R, making it a valuable tool for studying orexin signaling pathways. This compound is primarily utilized in research applications related to sleep regulation, appetite control, and neurodegenerative diseases.

Fumiporexant is a selective antagonist of the Orexin receptor 2 (OX2R), demonstrating oral bioavailability and effective penetration into the brain. This compound modulates the sleep-wake cycle and influences emotion-related pathways within the central nervous system. Fumiporexant is of significant interest in the study of neurological disorders, particularly insomnia and major depressive disorder.

Xenopus orexin A acts as a potent agonist of the orexin receptor OX1R, functioning as a neuropeptide that binds to G-protein-coupled receptors. This endogenous ligand plays a critical role in modulating various physiological processes, including appetite regulation and arousal. Research applications of Xenopus orexin A include studying energy homeostasis, sleep-wake cycles, and potential implications in metabolic disorders.

Orexin receptor antagonist 4 is a potent and selective antagonist of the orexin 2 receptor (OX2R), exhibiting an IC50 of 4.27 nM. This compound demonstrates a notable 61-fold selectivity for OX2R over the orexin 1 receptor (OX1R), which has an IC50 of 295 nM. Orexin receptor antagonist 4 is valuable for research applications exploring the role of orexin signaling in sleep regulation, energy metabolism, and various neurobiological processes.

Xenopus orexin B is a neuropeptide that acts as an agonist for the orexin receptor, specifically OX2R. This compound plays a crucial role in regulating various physiological processes, including arousal, appetite, and energy homeostasis. Its ability to activate orexin receptors makes it a valuable tool for research investigating sleep-wake cycles, metabolic disorders, and neurodegenerative diseases.

Orexin B (human) is an endogenous agonist that selectively targets the Orexin receptors, OX1 and OX2, with inhibition constants (Kis) of 420 nM and 36 nM, respectively. This compound plays a critical role in regulating arousal, appetite, and energy homeostasis. Orexin B is widely used in research applications focused on sleep disorders, metabolic syndromes, and neurodegenerative diseases, making it an essential tool for understanding Orexin signaling pathways.

OX2R-IN-1 is a selective antagonist of the OX2 receptor (OX2R), exhibiting a low cytotoxicity profile. With an IC50 value of 484 μM, it serves as a potential binder for OX2R studies. Notably, OX2R-IN-1 demonstrates the ability to penetrate the blood-brain barrier (BBB) and possesses a short half-life, making it suitable for research applications targeting central nervous system functions and disorders.

DMTr-2'-O-C16-rC(Ac)-3'-CE-phosphoramidite is an RNAi agent that specifically targets and inhibits Ataxin-2 (ATXN2). This compound plays a critical role in research focused on ATXN2-associated neurological disorders, facilitating the study of gene silencing mechanisms and potential therapeutic interventions. Its application may enhance understanding of disease pathways related to ATXN2.

Orexin receptor antagonist 7 selectively targets the orexin receptor 1 (OX1R) with a Ki value of 4.05 nM, demonstrating potent antagonistic activity. This compound shows negligible affinity for the orexin receptor 2 (OX2R) and minimal binding to opioid receptors (μ, δ, κ) with Ki values exceeding 1,000 nM. Orexin receptor antagonist 7 is suitable for research applications focused on opioid addiction and the elucidation of orexin-related pathways in various physiological and pathological contexts.

Rocavorexant is a selective antagonist of the orexin-1 receptor (OX1) with a pIC50 of 9.1 for human OX1 and a pIC50 of 6.0 for human OX2. This compound effectively inhibits the signaling pathways associated with orexin receptors, making it a valuable tool for investigating sleep disorders, appetite regulation, and related neurological conditions. Rocavorexant is utilized in research studies aimed at understanding the physiological roles of orexin signaling and for the development of therapeutic strategies targeting these pathways.

OX2R Agonist 1 is a selective agonist of the orexin receptor 2 (OX2R), exhibiting an effective concentration (EC50) of less than 100 nM. This compound is instrumental in studying the neurobiology of sleep regulation and is particularly relevant for research focused on excessive daytime sleepiness and narcolepsy. Its potent biological activity positions it as a valuable tool in the exploration of treatments for sleep disorders.

Orexin receptor antagonist 6 selectively targets the orexin 1 receptor (OX1) with a potent Ki of 8.5 nM and demonstrates more than 1180-fold selectivity for the OX2 receptor. This compound does not elicit conditioned place preference (CPP) or aversive effects and effectively inhibits CPP induced by psychoactive substances. Orexin receptor antagonist 6 is a valuable tool for investigating the role of orexin signaling in neurological diseases and related research applications.

DORA 42 is a dual antagonist of the orexin 1 and orexin 2 receptors. It demonstrates significant efficacy in promoting sleep in rat models, highlighting its potential utility in insomnia research. This compound serves as an important tool for studying the role of orexin receptors in sleep regulation and related disorders.

MK-8133 is a selective orexin-2 receptor antagonist that inhibits orexin signaling pathways. It has demonstrated efficacy in the modulation of sleep-wake cycles, making it a valuable tool for researching insomnia and other sleep disorders. This compound can be utilized in various experimental models to investigate the role of orexin in sleep regulation and potential therapeutic interventions.